Dr. Hawraa Issa, an academic in the College of Public Health, has recently co-authored a timely paper that emphasizes an effective therapeutic regimen for the treatment of COVID-19 by overcoming Angiotensin Converting Enzyme 2 (ACE2) inhibition. The article has been published in Frontiers in Medicine, a Q1 journal in medicine (miscellaneous). In this study, Dr. Issa and her colleagues encourage the adoption of Ang (1-7) agonists and convalescent plasma conjugated therapy for the treatment of COVID-19 patients. This therapeutic regimen—as argued by Issa et al.—is expected to be a safer choice since it possesses the proven ability to neutralize the virus while ensuring lung and cardiovascular protection through modulation of the inflammatory response. The full article can be accessed via the following link: https://www.frontiersin.org/articles/10.3389/fmed.2021.620990/full.
